UGT1A1: A Drug Target / Disease Biomarker (G54658)

Target Name: UGT1A1

NCBI ID: G54658

UGT1A1

UGT1A1: A Drug Target / Disease Biomarker

UGT1A1, also known as human UGT1A1 gene, is a gene that encodes a protein known as UGT1A1. UGT1A1 is a member of the UGT family of transmembrane proteins, which are involved in the detoxification of a wide variety of compounds, including drugs and other harmful substances. UGT1A1 is expressed in most tissues of the body and is responsible for the metabolism of a wide range of drugs, including many statins, benzodiazepines, and anticancer agents.

The UGT1A1 gene is located on chromosome 10q34 and has been implicated in a number of important biological processes. For example, studies have shown that UGT1A1 is involved in the detoxification of statins, which are commonly used to treat high cholesterol and heart disease. UGT1A1 has also been shown to be involved in the metabolism of other drugs that are used to treat a wide range of conditions, including cancer, neurodegenerative diseases, and mental illness.

In addition to its role in drug metabolism, UGT1A1 is also a potential drug target. Researchers have identified several potential drug-like compounds that can interact with UGT1A1 and enhance its activity in the detoxification of certain drugs. For example, one study identified a compound called N-acetyl-L-carnosine (NAC), which is known to be a weak inhibitor of UGT1A1. When NAC was added to a UGT1A1-expressing cell, it increased the activity of UGT1A1 in the metabolism of the drug simvastatin.

Another potential drug target for UGT1A1 is the protein known as GSTP, which is involved in the detoxification of many drugs, including many statins. GSTP is a transcription factor that is regulated by UGT1A1, and studies have shown that UGT1A1 can induce GSTP expression in response to the presence of certain drugs. This suggests that UGT1A1 may be a useful target for drugs that are used to treat statins or other drugs that are involved in the detoxification process.

In addition to its potential as a drug target, UGT1A1 is also a potential biomarker. Because UGT1A1 is involved in the detoxification of a wide variety of drugs, it is a potential indicator of drug exposure and may be useful as a biomarker for drug monitoring in patients treated with drugs that can cause harm. For example, one study identified UGT1A1 as a potential biomarker for simvastatin-induced hypersensitivity in patients treated with the drug simvastatin.

Another potential application of UGT1A1 as a biomarker is its involvement in the detoxification of cancer-causing agents. Many cancer-causing agents, including drugs, can be metabolized by UGT1A1 and are then excreted in the urine or feces. Therefore, UGT1A1 may be a useful indicator of the effectiveness of cancer treatments and the potential for drug-induced cancer.

In conclusion, UGT1A1 is a gene that encodes a protein involved in the detoxification of a wide variety of drugs. It is a potential drug target and a potential biomarker, and its involvement in the detoxification of drugs and cancer-causing agents makes it an important area of research. Further studies are needed to fully understand the role of UGT1A1 in these processes and to develop new treatments based on its potential as a drug target and biomarker.

Protein Name: UDP Glucuronosyltransferase Family 1 Member A1

Functions: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed:12181437, PubMed:15472229, PubMed:18004206, PubMed:18004212, PubMed:18719240, PubMed:19830808, PubMed:23288867). Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds (PubMed:12181437, PubMed:18004206, PubMed:18004212). Catalyzes the glucuronidation of endogenous estrogen hormones such as estradiol, estrone and estriol (PubMed:15472229, PubMed:18719240, PubMed:23288867). Involved in the glucuronidation of bilirubin, a degradation product occurring in the normal catabolic pathway that breaks down heme in vertebrates (PubMed:17187418, PubMed:18004206, PubMed:19830808). Also catalyzes the glucuronidation the isoflavones genistein, daidzein, glycitein, formononetin, biochanin A and prunetin, which are phytoestrogens with anticancer and cardiovascular properties (PubMed:18052087, PubMed:19545173). Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist losartan, a drug which can inhibit the effect of angiotensin II (PubMed:18674515). Involved in the biotransformation of 7-ethyl-10-hydroxycamptothecin (SN-38), the pharmacologically active metabolite of the anticancer drug irinotecan (PubMed:12181437, PubMed:18004212, PubMed:20610558)

The "UGT1A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGT1A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets